Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease
source: The Journal of Clinical Endocrinology & Metabolism
year: 2022
authors: Andrea Lora Kossler, Raymond Douglas, Chrysoula Dosiou
summary/abstract:Context: Thyroid eye disease (TED) is a sight-threatening and debilitating autoimmune condition, with limited therapies available, that often poses diagnostic and therapeutic challenges. In recent years, the treatment landscape has shifted to early intervention with targeted therapy.
Methods: A PubMed review of the literature was conducted for the period between 1979 and 2021. Search terms included thyroid eye disease, teprotumumab, targeted therapy, Graves disease, Graves ophthalmopathy, dysthyroid optic neuropathy, and related terms in different combinations. Novel biologic therapies for TED have emerged as alternatives to traditional steroid regimens in recent years. New insights into TED pathophysiology have uncovered the role of the insulin-like growth factor 1 receptor (IGF-1R) and led to the development of teprotumumab, an IGF-1R-inhibiting monoclonal antibody.
Results: Randomized clinical trials demonstrating the efficacy of teprotumumab for TED led to Food and Drug Administration approval. Teprotumumab is gradually replacing immunosuppressive agents as first-line therapy in the United States for active moderate-to-severe TED, while emerging reports also show its use in other stages of the disease. Recent data highlight risk factors for adverse events and screening protocols to maximize patient safety. Personalized therapeutic plans developed through effective partnership between endocrinologists and ophthalmologists aim to enhance the safety and outcomes of TED treatments and improve care for this complex disease.
Conclusion: TED management is shifting to an era of targeted therapy with multidisciplinary care. Teprotumumab has demonstrated superior efficacy to conventional treatments and has transformed our therapeutic and surgical algorithms. Clinical guidelines and additional studies are needed to further guide and refine therapy.
organization: Stanford University School of Medicine, USA; Cedars-Sinai Medical Center, USADOI: 10.1210/clinem/dgac168
read more full text
myBinderRelated Content
-
Efficacy of Orbital Radiotherapy in Moderate-to-Severe Active Graves’ Orbitopathy Including Long-Lasting Disease: ...Background: We aimed to explore the eff...
-
Angels Announcer Victor Rojas Stays Strong for His Wife in Her Health BattleShe braces herself for the worst. Stayin...
-
Prem Subramanian, MD, PhDPrem S. Subramanian is the Professor of ...
-
Substituting Potassium Iodide for Methimazole as the Treatment for Graves’ Disease During the First Trimester ...Background: To control hyperthyroidism ...
-
Total Thyroidectomy (Tx) Versus Thionamides (Antithyroid Drugs) in Patients With Moderate-to-Severe Graves’ Op...Background: Graves' disease (GD) is cha...
-
Does Early Response to Intravenous Glucocorticoids Predict the Final Outcome in Patients With Moderate-To-Severe and...Purpose: Intravenous glucocorticoids (i...
-
PREGO (Presentation of Graves’ Orbitopathy) Study: Changes in Referral Patterns to European Group On Graves...Background/Aims: The epidemiology of Gr...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Google